Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)

A Phase 4, Open-Label Trial to Evaluate the Safety and Effectiveness of Sebetralstat When Used as Preprocedural Short-term Prophylaxis in Patients With Hereditary Angioedema

This is a Phase 4, prospective, open-label trial to evaluate the safety and effectiveness of sebetralstat when used for STP for a qualifying procedures in patients 12 years of age or older with hereditary angioedema (HAE).

Study Overview

• Status: Not yet recruiting
• Conditions: Hereditary Angioedema
• Intervention / Treatment: Drug: KVD900 600 mg

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: KalVista Pharmaceuticals; Phone Number: 1 (857) 999-0075; Email: clinicalstudies@kalvista.com

Study Locations

• United States
  • Colorado
    • Colorado Springs, Colorado, United States, 80907
      • KalVista Investigative Site
      • Contact: Jennifer Potter; Phone Number: 719-314-0893; Email: jpotter@aacos.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male or female patients ≥12 years of age at time of Screening
2. Confirmed diagnosis of HAE Type I or II based on patient report
3. Patient has a qualifying procedure that is scheduled or planned to be scheduled to occur within 8 weeks of Screening
4. Patient has access to a commercial available on-demand treatment for HAE
5. Female patients of childbearing potential, including post-menarchal adolescents, must meet contraception requirements per Section 11.3. (Note: male patients do not require contraception)
6. Patients must be able to swallow trial tablets whole
7. Patients, as assessed by the Investigator, must be able to appropriately receive and store IMP, and be able to read, understand, and complete the questionnaire
8. Investigator believes that the patient is willing and able to adhere to all protocol requirements through the duration of the trial
9. Patient provides informed consent or assent (when applicable). A parent or legally authorized representative (LAR) must also provide signed informed consent when required

Exclusion Criteria:

1. A clinically significant history of poor response to bradykinin receptor 2 blocker, C1-INH therapy, or plasma kallikrein inhibitor therapy for the management of HAE, in the opinion of the Investigator
2. Use of angiotensin-converting enzyme (ACE) inhibitors within 7 days prior to the Screening Visit
3. Any estrogen-containing medications with systemic absorption (such as oral contraceptives including ethinylestradiol or hormonal replacement therapy) within 7 days prior to the Screening Visit
4. Patients who are taking strong cytochrome P450 (CYP)3A4 inhibitors or inducers or moderate CYP3A4 inducers within 2 weeks of the procedure
5. Any clinically significant comorbidity or systemic dysfunction, which in the opinion of the Investigator, would jeopardize the safety of the patient by participating in the trial
6. History of substance abuse or dependence that would interfere with the completion of the trial, as determined by the Investigator
7. Known hypersensitivity to sebetralstat or to any of the excipients
8. Participation in any gene therapy treatment or trial for HAE
9. Any pregnant or breastfeeding patient

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: KVD900 600 mg	Drug: KVD900 600 mg; KVD900 Tablet 600 mg (2 x 300 mg)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The number and proportion of STPs that did not result in an HAE attack within 24 hours after the start of the procedure will be summarized.	24 hours following the start of the procedure

Collaborators and Investigators

• Sponsor: KalVista Pharmaceuticals, Ltd.
• Investigators: Study Director: Study Director, KalVista Pharmaceuticals, Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): July 31, 2026
• Primary Completion (Estimated): November 29, 2027
• Study Completion (Estimated): December 6, 2027

Study Registration Dates

• First Submitted: June 12, 2026
• First Submitted That Met QC Criteria: June 12, 2026
• First Posted (Actual): June 17, 2026

Study Record Updates

• Last Update Posted (Actual): July 16, 2026
• Last Update Submitted That Met QC Criteria: July 14, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: KVD900
• Additional Relevant MeSH Terms: Hereditary Complement Deficiency Diseases; Primary Immunodeficiency Diseases; Vascular Diseases; Cardiovascular Diseases; Genetic Diseases, Inborn; Immune System Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immunologic Deficiency Syndromes; Skin Diseases; Urticaria; Skin Diseases, Vascular; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases; Angioedema; Angioedemas, Hereditary; sebetralstat
• Other Study ID Numbers: KVD900-401

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing but only after deidentification of individual patient data.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No